BCAX — Bicara Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $790.59m
- $300.88m
Annual income statement for Bicara Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Total Operating Expenses | 37.7 | 39.9 | 82.4 |
| Operating Profit | -37.7 | -39.9 | -82.4 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -37.8 | -52 | -67.8 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -37.8 | -52 | -68 |
| Net Income Before Extraordinary Items | |||
| Net Income | -37.8 | -52 | -68 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -37.8 | -52 | -68 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.731 | -1 | -4.05 |